The abstract is read at the publisher; the summary is JClub's.
EPAC2 inhibition in Fmr1 knockout mice restores cortical circuit function and ameliorates multiple behavioral phenotypes, identifying EPAC2 as a therapeutic target in fragile X syndrome.
- Why it matters: Fragile X syndrome is linked to an excitation/inhibition imbalance, but cell-type-specific molecular drivers and actionable targets remain unclear.
- What they did: The study used cell-type-specific mRNA sequencing to profile cortical excitatory (Camk2) and inhibitory (Pvalb) neuron translatomes in Fmr1 KO mice, then integrated transcriptomic, circuit, and behavioral readouts to prioritize targets.
- The result: Among 184 concordantly dysregulated genes across both cell types, only Rapgef4/Epac2 was also an FMRP target, brain-enriched, and associated with neurodevelopmental disorders; blocking EPAC2 with a specific antagonist normalized circuit and behavior.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.